Axsome Therapeutics AXSM Intangible Amortization
Intangible Amortization at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's intangible amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's intangible amortization?
- Axsome Therapeutics (AXSM) reported intangible amortization of $1.57M in Q1 2026.
- How has Axsome Therapeutics's intangible amortization changed year-over-year?
- Axsome Therapeutics's intangible amortization decreased by 0.0% year-over-year, from $1.57M to $1.57M.
- What is the long-term trend for Axsome Therapeutics's intangible amortization?
- Over 3 years (2022 to 2025), Axsome Therapeutics's intangible amortization has grown at a 15.5% compound annual growth rate (CAGR), from $4.14M to $6.38M.
- What does intangible amortization mean?
- The non-cash expense of writing down the value of acquired intangible assets over time.
- How do you interpret intangible amortization?
- Higher values often reflect significant past M&A activity or heavy investment in intellectual property.
- How does intangible amortization compare across companies?
- Standard for companies with significant acquired intellectual property or R&D portfolios.